Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 446

1.

MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB.

Cordas Dos Santos DM, Eilers J, Sosa Vizcaino A, Orlova E, Zimmermann M, Stanulla M, Schrappe M, Börner K, Grimm D, Muckenthaler MU, Kulozik AE, Kunz JB.

BMC Cancer. 2018 Jun 18;18(1):663. doi: 10.1186/s12885-018-4525-0.

PMID:
29914415
2.

Lmo2 expression defines tumor cell identity during T-cell leukemogenesis.

García-Ramírez I, Bhatia S, Rodríguez-Hernández G, González-Herrero I, Walter C, González de Tena-Dávila S, Parvin S, Haas O, Woessmann W, Stanulla M, Schrappe M, Dugas M, Natkunam Y, Orfao A, Domínguez V, Pintado B, Blanco O, Alonso-López D, De Las Rivas J, Martín-Lorenzo A, Jiménez R, García Criado FJ, García Cenador MB, Lossos IS, Vicente-Dueñas C, Borkhardt A, Hauer J, Sánchez-García I.

EMBO J. 2018 Jun 7. pii: e98783. doi: 10.15252/embj.201798783. [Epub ahead of print]

3.

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.

Hrusak O, De Haas V, Stancikova J, Vakrmanova B, Janotova I, Mejstrikova E, Capek V, Trka J, Zaliova M, Luks A, Bleckmann K, Möricke A, Irving J, Konatkowska B, Alexander TB, Inaba H, Schmiegelow K, Stokley S, Zemanova Z, Moorman AV, Rossi JG, Felice MS, Dalla-Pozza L, Morales J, Dworzak M, Buldini B, Basso G, Campbell M, Cabrera ME, Marinov N, Elitzur S, Izraeli S, Luria D, Feuerstein T, Kolenova A, Svec P, Kreminska O, Rabin KR, Polychronopoulou S, da Costa E, Marquart HV, Kattamis A, Ratei R, Reinhardt D, Choi JK, Schrappe M, Stary J.

Blood. 2018 May 2. pii: blood-2017-12-821363. doi: 10.1182/blood-2017-12-821363. [Epub ahead of print]

PMID:
29720486
4.

Osteonecrosis in children with acute lymphoblastic leukemia at initial diagnosis and prior to any chemotherapy.

Krull K, Kunstreich M, Bronsema A, Bleckmann K, Classen CF, Erdlenbruch B, Jorch N, Kolb R, Leipold A, Moser O, Prokop A, Scheurlen W, Steinbach D, Klasen-Sansone J, Klee D, Escherich G, Moericke A, Schrappe M, Borkhardt A, Kuhlen M.

Leuk Lymphoma. 2018 May 2:1-7. doi: 10.1080/10428194.2018.1466292. [Epub ahead of print]

PMID:
29718744
5.

Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia.

Vijayakrishnan J, Studd J, Broderick P, Kinnersley B, Holroyd A, Law PJ, Kumar R, Allan JM, Harrison CJ, Moorman AV, Vora A, Roman E, Rachakonda S, Kinsey SE, Sheridan E, Thompson PD, Irving JA, Koehler R, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Jöckel KH, Easton DF, Pharaoh PDP, Dunning AM, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Greaves M, Zimmerman M, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS; PRACTICAL Consortium.

Nat Commun. 2018 Apr 9;9(1):1340. doi: 10.1038/s41467-018-03178-z.

6.

IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.

Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, Eckert C, Te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M; TRANSCALL Consortium; International BFM Study Group.

J Clin Oncol. 2018 Apr 20;36(12):1240-1249. doi: 10.1200/JCO.2017.74.3617. Epub 2018 Mar 2.

PMID:
29498923
7.

NGS-based methylation profiling differentiates TCF3-HLF and TCF3-PBX1 positive B-cell acute lymphoblastic leukemia.

Kachroo P, Szymczak S, Heinsen FA, Forster M, Bethune J, Hemmrich-Stanisak G, Baker L, Schrappe M, Stanulla M, Franke A.

Epigenomics. 2018 Feb;10(2):133-147. doi: 10.2217/epi-2017-0080. Epub 2018 Jan 15.

PMID:
29334255
8.

[Position Paper of The AG Digital Health DNVF on Digital Health Applications: Framework Conditions For Use in Health Care, Structural Development and Science].

Vollmar HC, Kramer U, Müller H, Griemmert M, Noelle G, Schrappe M.

Gesundheitswesen. 2017 Dec;79(12):1080-1092. doi: 10.1055/s-0043-122233. Epub 2017 Dec 29. German.

PMID:
29287301
9.

Therapeutic Drug Monitoring of Asparaginase Activity-Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 Trial.

Lanvers-Kaminsky C, Rüffer A, Würthwein G, Gerss J, Zucchetti M, Ballerini A, Attarbaschi A, Smisek P, Nath C, Lee S, Elitzur S, Zimmermann M, Möricke A, Schrappe M, Rizzari C, Boos J.

Ther Drug Monit. 2018 Feb;40(1):93-102. doi: 10.1097/FTD.0000000000000472.

PMID:
29210976
10.

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.

Driessen EMC, de Lorenzo P, Campbell M, Felice M, Ferster A, Hann I, Vora A, Hovi L, Escherich G, Li CK, Mann G, Leblanc T, Locatelli F, Biondi A, Rubnitz J, Schrappe M, Silverman L, Stary J, Suppiah R, Szczepanski T, Valsecchi M, Pieters R.

Leukemia. 2017 Dec;31(12):2854. doi: 10.1038/leu.2017.279.

PMID:
29210366
11.

A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.

Sutton R, Venn NC, Law T, Boer JM, Trahair TN, Ng A, Den Boer ML, Dissanayake A, Giles JE, Dalzell P, Mayoh C, Barbaric D, Revesz T, Alvaro F, Pieters R, Haber M, Norris MD, Schrappe M, Dalla Pozza L, Marshall GM.

Br J Haematol. 2018 Feb;180(4):550-562. doi: 10.1111/bjh.15056. Epub 2017 Nov 30.

PMID:
29194562
12.

Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial.

Kuhlen M, Willasch AM, Dalle JH, Wachowiak J, Yaniv I, Ifversen M, Sedlacek P, Guengoer T, Lang P, Bader P, Sufliarska S, Balduzzi A, Strahm B, von Luettichau I, Hoell JI, Borkhardt A, Klingebiel T, Schrappe M, von Stackelberg A, Glogova E, Poetschger U, Meisel R, Peters C.

Br J Haematol. 2018 Jan;180(1):82-89. doi: 10.1111/bjh.14965. Epub 2017 Nov 28.

PMID:
29193007
13.

Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).

Schrappe M, Bleckmann K, Zimmermann M, Biondi A, Möricke A, Locatelli F, Cario G, Rizzari C, Attarbaschi A, Valsecchi MG, Bartram CR, Barisone E, Niggli F, Niemeyer C, Testi AM, Mann G, Ziino O, Schäfer B, Panzer-Grümayer R, Beier R, Parasole R, Göhring G, Ludwig WD, Casale F, Schlegel PG, Basso G, Conter V.

J Clin Oncol. 2018 Jan 20;36(3):244-253. doi: 10.1200/JCO.2017.74.4946. Epub 2017 Nov 17.

PMID:
29148893
14.

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.

Cazzaniga G, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen HO, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari GM, Bleckmann K, Pieters R, van der Velden V, Stary J, Zuna J, Escherich G, Stadt UZ, Aricò M, Conter V, Schrappe M, Valsecchi MG, Biondi A.

Haematologica. 2018 Jan;103(1):107-115. doi: 10.3324/haematol.2017.176917. Epub 2017 Oct 27.

15.

Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.

Landmann E, Burkhardt B, Zimmermann M, Meyer U, Woessmann W, Klapper W, Wrobel G, Rosolen A, Pillon M, Escherich G, Attarbaschi A, Beishuizen A, Mellgren K, Wynn R, Ratei R, Plesa A, Schrappe M, Reiter A, Bergeron C, Patte C, Bertrand Y.

Haematologica. 2017 Dec;102(12):2086-2096. doi: 10.3324/haematol.2015.139162. Epub 2017 Oct 5.

16.

[Memorandum III, Part 3: Quality of Care and Patient Safety Research Methods].

Geraedts M, Drösler SE, Döbler K, Eberlein-Gonska M, Heller G, Kuske S, Manser T, Sens B, Stausberg J, Schrappe M.

Gesundheitswesen. 2017 Oct;79(10):e95-e124. doi: 10.1055/s-0043-112431. Epub 2017 Sep 28. German.

17.

Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL.

Locatelli F, Valsecchi MG, Möricke A, Zimmermann M, Gruhn B, Biondi A, Kulozik AE, Silvestri D, Bodmer N, Putti MC, Burdach S, Micalizzi C, Teigler-Schlegel A, Ritter J, Pession A, Cario G, Bielack S, Basso G, Klingebiel T, Vinti L, Rizzari C, Attarbaschi A, Santoro N, Parasole R, Mann G, Karawajew L, Haas OA, Conter V, Schrappe M.

Blood. 2017 Nov 9;130(19):2146-2149. doi: 10.1182/blood-2017-05-782086. Epub 2017 Sep 22. No abstract available.

PMID:
28939722
18.

Prevalence of sleep apnea and cardiovascular risk factors in patients with hypertension in a day hospital model.

Borsini E, Blanco M, Bosio M, Schrappe M, Ernst G, Nosetto D, Gaggioli N, Salvado A, Manuale O, Schiavone M.

Clin Exp Hypertens. 2018;40(3):231-237. doi: 10.1080/10641963.2017.1356841. Epub 2017 Sep 5.

PMID:
28872361
19.

The role of constitutive activation of FMS-related tyrosine kinase-3 and NRas/KRas mutational status in infants with KMT2A-rearranged acute lymphoblastic leukemia.

Fedders H, Alsadeq A, Schmäh J, Vogiatzi F, Zimmermann M, Möricke A, Lenk L, Stadt UZ, Horstmann MA, Pieters R, Schrappe M, Stanulla M, Cario G, Schewe DM.

Haematologica. 2017 Nov;102(11):e438-e442. doi: 10.3324/haematol.2017.169870. Epub 2017 Aug 24. No abstract available.

20.

Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.

Kuhlen M, Bleckmann K, Möricke A, Schrappe M, Vieth S, Escherich G, Bronsema A, Vonalt A, Queudeville M, Zwaan CM, Ebinger M, Debatin KM, Klingebiel T, Koscielniak E, Rossig C, Burkhardt B, Kolb R, Eckert C, Borkhardt A, von Stackelberg A, Chen-Santel C.

Br J Haematol. 2017 Oct;179(2):272-283. doi: 10.1111/bjh.14877. Epub 2017 Aug 2.

PMID:
28771662
21.

The MLL recombinome of acute leukemias in 2017.

Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, Sutton R, Venn NC, Emerenciano M, Pombo-de-Oliveira MS, Barbieri Blunck C, Almeida Lopes B, Zuna J, Trka J, Ballerini P, Lapillonne H, De Braekeleer M, Cazzaniga G, Corral Abascal L, van der Velden VHJ, Delabesse E, Park TS, Oh SH, Silva MLM, Lund-Aho T, Juvonen V, Moore AS, Heidenreich O, Vormoor J, Zerkalenkova E, Olshanskaya Y, Bueno C, Menendez P, Teigler-Schlegel A, Zur Stadt U, Lentes J, Göhring G, Kustanovich A, Aleinikova O, Schäfer BW, Kubetzko S, Madsen HO, Gruhn B, Duarte X, Gameiro P, Lippert E, Bidet A, Cayuela JM, Clappier E, Alonso CN, Zwaan CM, van den Heuvel-Eibrink MM, Izraeli S, Trakhtenbrot L, Archer P, Hancock J, Möricke A, Alten J, Schrappe M, Stanulla M, Strehl S, Attarbaschi A, Dworzak M, Haas OA, Panzer-Grümayer R, Sedék L, Szczepański T, Caye A, Suarez L, Cavé H, Marschalek R.

Leukemia. 2018 Feb;32(2):273-284. doi: 10.1038/leu.2017.213. Epub 2017 Jul 13.

22.

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts.

Schewe DM, Alsadeq A, Sattler C, Lenk L, Vogiatzi F, Cario G, Vieth S, Valerius T, Rosskopf S, Meyersieck F, Alten J, Schrappe M, Gramatzki M, Peipp M, Kellner C.

Blood. 2017 Sep 28;130(13):1543-1552. doi: 10.1182/blood-2017-01-764316. Epub 2017 Jul 11.

PMID:
28698205
23.

Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper.

Aapro M, Astier A, Audisio R, Banks I, Bedossa P, Brain E, Cameron D, Casali P, Chiti A, De Mattos-Arruda L, Kelly D, Lacombe D, Nilsson PJ, Piccart M, Poortmans P, Riklund K, Saeter G, Schrappe M, Soffietti R, Travado L, van Poppel H, Wait S, Naredi P.

Eur J Cancer. 2017 Sep;82:193-202. doi: 10.1016/j.ejca.2017.04.014. Epub 2017 Jul 7.

24.

Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.

Hinze L, Möricke A, Zimmermann M, Junk S, Cario G, Dagdan E, Kratz CP, Conter V, Schrappe M, Stanulla M.

Leukemia. 2017 Aug;31(8):1840-1842. doi: 10.1038/leu.2017.154. Epub 2017 May 22. No abstract available.

PMID:
28529312
25.

Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.

Schwartzman O, Savino AM, Gombert M, Palmi C, Cario G, Schrappe M, Eckert C, von Stackelberg A, Huang JY, Hameiri-Grossman M, Avigad S, Te Kronnie G, Geron I, Birger Y, Rein A, Zarfati G, Fischer U, Mukamel Z, Stanulla M, Biondi A, Cazzaniga G, Vetere A, Wagner BK, Chen Z, Chen SJ, Tanay A, Borkhardt A, Izraeli S.

Proc Natl Acad Sci U S A. 2017 May 16;114(20):E4030-E4039. doi: 10.1073/pnas.1702489114. Epub 2017 May 1.

26.

Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood.

Schmäh J, Fedders B, Panzer-Grümayer R, Fischer S, Zimmermann M, Dagdan E, Bens S, Schewe D, Moericke A, Alten J, Bleckmann K, Siebert R, Schrappe M, Stanulla M, Cario G.

Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26539. Epub 2017 Apr 1.

PMID:
28371317
27.

Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia.

Würthwein G, Lanvers-Kaminsky C, Hempel G, Gastine S, Möricke A, Schrappe M, Karlsson MO, Boos J.

Eur J Drug Metab Pharmacokinet. 2017 Dec;42(6):955-963. doi: 10.1007/s13318-017-0410-5.

PMID:
28349335
28.

Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols.

Rohde M, Bonn BR, Zimmermann M, Lange J, Möricke A, Klapper W, Oschlies I, Szczepanowski M, Nagel I, Schrappe M; MMML-MYC-SYS Project; ICGC MMML-Seq Project, Loeffler M, Siebert R, Reiter A, Burkhardt B.

Haematologica. 2017 Jun;102(6):1091-1098. doi: 10.3324/haematol.2016.156885. Epub 2017 Feb 16.

29.

AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia.

Dworzak MN, Buldini B, Gaipa G, Ratei R, Hrusak O, Luria D, Rosenthal E, Bourquin JP, Sartor M, Schumich A, Karawajew L, Mejstrikova E, Maglia O, Mann G, Ludwig WD, Biondi A, Schrappe M, Basso G; International-BFM-FLOW-network.

Cytometry B Clin Cytom. 2018 Jan;94(1):82-93. doi: 10.1002/cyto.b.21518. Epub 2017 Feb 21.

PMID:
28187514
30.

Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology.

Ripperger T, Bielack SS, Borkhardt A, Brecht IB, Burkhardt B, Calaminus G, Debatin KM, Deubzer H, Dirksen U, Eckert C, Eggert A, Erlacher M, Fleischhack G, Frühwald MC, Gnekow A, Goehring G, Graf N, Hanenberg H, Hauer J, Hero B, Hettmer S, von Hoff K, Horstmann M, Hoyer J, Illig T, Kaatsch P, Kappler R, Kerl K, Klingebiel T, Kontny U, Kordes U, Körholz D, Koscielniak E, Kramm CM, Kuhlen M, Kulozik AE, Lamottke B, Leuschner I, Lohmann DR, Meinhardt A, Metzler M, Meyer LH, Moser O, Nathrath M, Niemeyer CM, Nustede R, Pajtler KW, Paret C, Rasche M, Reinhardt D, Rieß O, Russo A, Rutkowski S, Schlegelberger B, Schneider D, Schneppenheim R, Schrappe M, Schroeder C, von Schweinitz D, Simon T, Sparber-Sauer M, Spix C, Stanulla M, Steinemann D, Strahm B, Temming P, Thomay K, von Bueren AO, Vorwerk P, Witt O, Wlodarski M, Wössmann W, Zenker M, Zimmermann S, Pfister SM, Kratz CP.

Am J Med Genet A. 2017 Apr;173(4):1017-1037. doi: 10.1002/ajmg.a.38142. Epub 2017 Feb 7. Review.

PMID:
28168833
31.

Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia.

Richter-Pechańska P, Kunz JB, Hof J, Zimmermann M, Rausch T, Bandapalli OR, Orlova E, Scapinello G, Sagi JC, Stanulla M, Schrappe M, Cario G, Kirschner-Schwabe R, Eckert C, Benes V, Korbel JO, Muckenthaler MU, Kulozik AE.

Blood Cancer J. 2017 Feb 3;7(2):e523. doi: 10.1038/bcj.2017.3.

32.

Osteonecrosis develops independently from radiological leukemic infiltration of bone in adolescents with acute lymphoblastic leukemia - first findings of the OPAL trial.

Krull K, Kunstreich M, Klasen-Sansone J, Kloetgen A, Gruener F, Escherich G, Bleckmann K, Moericke A, Schrappe M, Jorch N, Steinbach D, Classen CF, Guggemos A, Kolb R, Klee D, Borkhardt A, Kuhlen M.

Leuk Lymphoma. 2017 Oct;58(10):2363-2369. doi: 10.1080/10428194.2017.1280605. Epub 2017 Jan 31.

PMID:
28140726
33.

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.

Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, Richter-Pechanska P, Marovca B, Pail O, Jenni S, Diaz-Flores E, Chang BH, Brown TJ, Collins RH, Uhrig S, Balasubramanian GP, Bandapalli OR, Higi S, Eugster S, Voegeli P, Delorenzi M, Cario G, Loh ML, Schrappe M, Stanulla M, Kulozik AE, Muckenthaler MU, Saha V, Irving JA, Meisel R, Radimerski T, Von Stackelberg A, Eckert C, Tyner JW, Horvath P, Bornhauser BC, Bourquin JP.

Blood. 2017 Mar 16;129(11):e26-e37. doi: 10.1182/blood-2016-09-738070. Epub 2017 Jan 25.

34.

RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts.

Gieseler-Halbach S, Meltendorf S, Pierau M, Weinert S, Heidel FH, Fischer T, Handschuh J, Braun-Dullaeus RC, Schrappe M, Lindquist JA, Mertens PR, Thomas U, Brunner-Weinzierl MC.

Cell Death Differ. 2017 Feb;24(2):371-383. doi: 10.1038/cdd.2016.141. Epub 2016 Dec 23.

35.

Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia.

Vesely C, Frech C, Eckert C, Cario G, Mecklenbräuker A, Zur Stadt U, Nebral K, Kraler F, Fischer S, Attarbaschi A, Schuster M, Bock C, Cavé H, von Stackelberg A, Schrappe M, Horstmann MA, Mann G, Haas OA, Panzer-Grümayer R.

Leukemia. 2017 Jul;31(7):1491-1501. doi: 10.1038/leu.2016.365. Epub 2016 Nov 30.

36.

DNA methylation profiling of pediatric B-cell lymphoblastic leukemia with KMT2A rearrangement identifies hypomethylation at enhancer sites.

Bergmann AK, Castellano G, Alten J, Ammerpohl O, Kolarova J, Nordlund J, Martin-Subero JI, Schrappe M, Siebert R.

Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26251. Epub 2016 Oct 27.

PMID:
27786413
37.

T-cell acute lymphoblastic leukemia in infants has distinct genetic and epigenetic features compared to childhood cases.

Doerrenberg M, Kloetgen A, Hezaveh K, Wössmann W, Bleckmann K, Stanulla M, Schrappe M, McHardy AC, Borkhardt A, Hoell JI.

Genes Chromosomes Cancer. 2017 Feb;56(2):159-167. doi: 10.1002/gcc.22423. Epub 2016 Oct 26.

PMID:
27717083
38.

Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies.

Tamm R, Mägi R, Tremmel R, Winter S, Mihailov E, Smid A, Möricke A, Klein K, Schrappe M, Stanulla M, Houlston R, Weinshilboum R, Mlinarič Raščan I, Metspalu A, Milani L, Schwab M, Schaeffeler E.

Clin Pharmacol Ther. 2017 May;101(5):684-695. doi: 10.1002/cpt.540. Epub 2017 Feb 1. Review.

39.

[Health services Research Faces New Challenges: Consequences for Definition and Concept].

Schrappe M, Pfaff H.

Gesundheitswesen. 2016 Nov;78(11):689-694. Epub 2016 Oct 18. Review. German.

PMID:
27756086
40.

A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1.

Vijayakrishnan J, Kumar R, Henrion MY, Moorman AV, Rachakonda PS, Hosen I, da Silva Filho MI, Holroyd A, Dobbins SE, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson PD, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Jöckel KH, Greaves M, Harrison CJ, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS.

Leukemia. 2017 Mar;31(3):573-579. doi: 10.1038/leu.2016.271. Epub 2016 Oct 3.

41.

The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system.

Alsadeq A, Fedders H, Vokuhl C, Belau NM, Zimmermann M, Wirbelauer T, Spielberg S, Vossen-Gajcy M, Cario G, Schrappe M, Schewe DM.

Haematologica. 2017 Feb;102(2):346-355. doi: 10.3324/haematol.2016.147744. Epub 2016 Sep 29.

42.

CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia.

Palmi C, Savino AM, Silvestri D, Bronzini I, Cario G, Paganin M, Buldini B, Galbiati M, Muckenthaler MU, Bugarin C, Della Mina P, Nagel S, Barisone E, Casale F, Locatelli F, Lo Nigro L, Micalizzi C, Parasole R, Pession A, Putti MC, Santoro N, Testi AM, Ziino O, Kulozik AE, Zimmermann M, Schrappe M, Villa A, Gaipa G, Basso G, Biondi A, Valsecchi MG, Stanulla M, Conter V, Te Kronnie G, Cazzaniga G.

Oncotarget. 2016 Sep 13;7(37):59260-59272. doi: 10.18632/oncotarget.10610.

43.

Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia.

Lilljebjörn H, Henningsson R, Hyrenius-Wittsten A, Olsson L, Orsmark-Pietras C, von Palffy S, Askmyr M, Rissler M, Schrappe M, Cario G, Castor A, Pronk CJ, Behrendtz M, Mitelman F, Johansson B, Paulsson K, Andersson AK, Fontes M, Fioretos T.

Nat Commun. 2016 Jun 6;7:11790. doi: 10.1038/ncomms11790.

44.

Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL.

McComb S, Aguadé-Gorgorió J, Harder L, Marovca B, Cario G, Eckert C, Schrappe M, Stanulla M, von Stackelberg A, Bourquin JP, Bornhauser BC.

Sci Transl Med. 2016 May 18;8(339):339ra70. doi: 10.1126/scitranslmed.aad2986.

PMID:
27194728
45.

Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia.

Zuna J, Moericke A, Arens M, Koehler R, Panzer-Grümayer R, Bartram CR, Fischer S, Fronkova E, Zaliova M, Schrauder A, Stanulla M, Zimmermann M, Trka J, Stary J, Attarbaschi A, Mann G, Schrappe M, Cario G.

Br J Haematol. 2016 Jun;173(5):742-8. doi: 10.1111/bjh.13989. Epub 2016 Feb 23.

PMID:
26913693
46.

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.

Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, Locatelli F, Cazzaniga G, Niggli F, Aricò M, Bartram CR, Attarbaschi A, Silvestri D, Beier R, Basso G, Ratei R, Kulozik AE, Lo Nigro L, Kremens B, Greiner J, Parasole R, Harbott J, Caruso R, von Stackelberg A, Barisone E, Rössig C, Conter V, Schrappe M.

Blood. 2016 Apr 28;127(17):2101-12. doi: 10.1182/blood-2015-09-670729. Epub 2016 Feb 17.

47.

Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia.

Preuner S, Peters C, Pötschger U, Daxberger H, Fritsch G, Geyeregger R, Schrauder A, von Stackelberg A, Schrappe M, Bader P, Ebell W, Eckert C, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Lawitschka A, Mann G, Panzer-Grümayer R, Güngör T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Lion T.

Haematologica. 2016 Jun;101(6):741-6. doi: 10.3324/haematol.2015.135137. Epub 2016 Feb 11.

48.

Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.

Bleckmann K, Schrappe M.

Br J Haematol. 2016 Mar;172(6):855-69. doi: 10.1111/bjh.13896. Epub 2016 Jan 15. Review.

PMID:
26773444
49.

Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy.

Vora A, Andreano A, Pui CH, Hunger SP, Schrappe M, Moericke A, Biondi A, Escherich G, Silverman LB, Goulden N, Taskinen M, Pieters R, Horibe K, Devidas M, Locatelli F, Valsecchi MG.

J Clin Oncol. 2016 Mar 20;34(9):919-26. doi: 10.1200/JCO.2015.64.2850. Epub 2016 Jan 11.

50.

Preexisting conditions in pediatric ALL patients: Spectrum, frequency and clinical impact.

Schütte P, Möricke A, Zimmermann M, Bleckmann K, Reismüller B, Attarbaschi A, Mann G, Bodmer N, Niggli F, Schrappe M, Stanulla M, Kratz CP.

Eur J Med Genet. 2016 Mar;59(3):143-51. doi: 10.1016/j.ejmg.2015.12.008. Epub 2015 Dec 28. Review.

PMID:
26732628

Supplemental Content

Loading ...
Support Center